HOWL logo

WEREWOLF THERAPEUTICS INC

HOWLNASDAQ
πŸ† #4222 by market capEarnings Mar 25US Equity
$0.95β–Ό $0.04 (βˆ’3.97%)
Market closed Β· at close
πŸ””
Track HOWL
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 4.0%
7dβ–Ό 3.4%
14dβ–Ό 5.8%
30dβ–Ό 4.7%
ytdβ–² 50.2%
1yβ–² 6.4%
🏦Market Cap
$46M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-100.0%
Declining
πŸ“ŠGross Margin
80.4%
High
πŸ’΅FCF Margin
-114.1%
Thin
βš–οΈP/S Ratio
2.2x
Cheap
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$0.93 – $0.99
52-Week Range
$0.27 – $1.20
Volume (shares)
374,029
Avg Volume (shares)
β€”
Shares Outstanding
48.6M
Next Earnings
2027-03-25

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
$21M
P/E Ratio
-1.6
P/S Ratio
2.2x
EPS (TTM)
$-0.58
Dividend Yield
0.00%
Dilution (1yr)
+5.2%
HOWL logo

WEREWOLF THERAPEUTICS INC

HOWL
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0β–Ό βˆ’100.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
3.8%β–Ό βˆ’95.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$61Mβ–Ό βˆ’17.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$60Mβ–² +6.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
46.8Mβ–² +5.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$19Mβ–Ό βˆ’$55M YoY
StockOtter Β· stockotter.space

About WEREWOLF THERAPEUTICS INC

Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100

Analyst Ratings

β“˜
Consensus
Sell
6 analysts
Strong Buy0
Buy0
Hold3
Sell1
Strong Sell2
Ratings as of Nov 2026

Latest News & Updates

GlobeNewsWireΒ·13d ago

Werewolf Therapeutics' Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer's (SITC) 2026 Annual Meeting

WALTHAM, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the β€œCompany” or β€œWerewolf”) (Nasdaq: HOWL), a biopharmaceutical company that has developed conditionally activated therapeutics engineered t

GlobeNewsWireΒ·23d ago

Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 2026 Annual Meeting

WALTHAM, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the β€œCompany” or β€œWerewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated th

Zacks Investment ResearchΒ·Oct 13

Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why

Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment ResearchΒ·Oct 9

New Strong Buy Stocks for October 9th

LITE, HOWL, PERI, GSBD and GFF have been added to the Zacks Rank #1 (Strong Buy) List on October 9th, 2026.

Defense WorldΒ·Sep 30

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Stock Has Average Target Price of $4.00 According to Analysts

Shares of Werewolf Therapeutics, Inc. (NASDAQ: HOWL - Get Free Report) have been assigned an average rating of "Hold" from the seven ratings firms that are currently covering the stock, Marketbeat.com reports. One resear

GlobeNewsWireΒ·Sep 24

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX)

BALA CYNWYD, Pa., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmit